Welcome to our dedicated page for Organogenesis Hldgs news (Ticker: ORGO), a resource for investors and traders seeking the latest updates and insights on Organogenesis Hldgs stock.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company focused on product solutions for the Advanced Wound Care and Surgical & Sports Medicine markets. The Organogenesis news feed highlights company announcements, clinical updates, financial results, and regulatory developments that help investors and healthcare professionals understand how the business is evolving.
News about Organogenesis frequently covers its regenerative medicine portfolio and its position in the skin substitutes and cellular and tissue-based products (CTP) market. The company issues press releases on quarterly and year-to-date financial performance, including net product revenue from Advanced Wound Care and Surgical & Sports Medicine products, net income or loss, and adjusted metrics such as adjusted net income and adjusted EBITDA. These updates often include management commentary on market conditions, reimbursement dynamics, and expectations for future periods.
A major theme in Organogenesis news is the development of ReNu, a cryopreserved amniotic suspension allograft for symptomatic knee osteoarthritis. The company publishes detailed updates on Phase 3 randomized controlled trials, including pain and function outcomes, safety observations, and plans for regulatory submissions. Announcements have described FDA Regenerative Medicine Advanced Therapy (RMAT) designation for ReNu, plans for a Biologics License Application (BLA), and the initiation of a rolling BLA submission.
Additional news items include commentary on Centers for Medicare & Medicaid Services (CMS) payment reforms for skin substitutes/CTPs, participation in investor conferences, and corporate governance developments such as inducement equity grants and stockholder meeting results. By following this page, readers can review a chronological record of how Organogenesis communicates its financial performance, clinical progress, reimbursement environment, and corporate actions.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its second quarter fiscal year 2025 earnings release for August 7, 2025, after market close.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update. Investors can join via webcast or teleconference using the number 800-715-9871 (646-307-1963 for international) with access code 634899. The webcast will be available on the company's investor relations website for approximately one year.
Organogenesis (Nasdaq: ORGO), a regenerative medicine company, has expressed support for the Centers for Medicare & Medicaid Services' (CMS) proposed new payment methodology for skin substitutes in CY 2026. The proposal introduces a per centimeter square payment system based on FDA classification across both physician office and hospital outpatient settings.
CEO Gary S. Gillheeney highlighted that the new structure aims to reduce system abuse and Medicare spending while ensuring consistent payment across care sites. The proposal notably recognizes PMA products' clinical differentiation and seeks to expand access to innovative wound healing technologies that help reduce amputations and complications.
Organogenesis Holdings (Nasdaq: ORGO) supports the U.S. Centers for Medicare & Medicaid Services' (CMS) decision to delay the implementation of local coverage determinations (LCDs) for skin substitute grafts and cellular tissue-based products (CTP) used in treating diabetic foot ulcers and venous leg ulcers.
The company endorses CMS's move to review coverage policies ensuring patient access to products with high-quality effectiveness evidence, including real-world evidence. CEO Gary S. Gillheeney Sr. recommends CMS implement an integrated coverage and payment policy to address rising Medicare costs while maintaining cost-effective patient care and innovation.
As a four-decade leader in regenerative medicine, Organogenesis pioneers bioengineered living cell products and manufactures advanced wound care therapies, with multiple technology platforms supporting clinically proven solutions that improve outcomes while reducing overall care costs.
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has scheduled its first quarter 2025 financial results announcement for May 8, 2025, after market close.
Management will conduct a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly results and provide a corporate update, followed by a Q&A session. The event will be accessible via webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (NASDAQ: ORGO) reported strong Q4 2024 financial results with net revenue of $126.7 million, up 27% from Q4 2023. The company achieved Q4 net income of $7.7 million compared to a net loss of $0.6 million in Q4 2023.
For full-year 2024, revenue reached $482.0 million, an 11% increase from 2023, driven by Advanced Wound Care products (+12% to $453.6M) and Surgical & Sports Medicine products (+3% to $28.4M). The company ended 2024 with $136.2 million in cash and no outstanding debt.
For 2025 guidance, Organogenesis expects:
- Net revenue between $480.0-$535.0 million
- Net income between $9.5-$38.8 million
- Adjusted EBITDA between $43.6-$83.2 million
Organogenesis Holdings (Nasdaq: ORGO), a regenerative medicine company specializing in Advanced Wound Care and Surgical and Sports Medicine markets, has announced it will release its fourth quarter and fiscal year 2024 financial results after market close on February 27th, 2025.
Management will host a conference call at 5:00 p.m. Eastern Time on the same day to discuss quarterly and annual results, provide a corporate update, and conduct a Q&A session. The event will be accessible via live webcast through the company's investor relations website, where it will remain archived for approximately one year.
Organogenesis Holdings (Nasdaq: ORGO) announced plans to expand its manufacturing capacity through a long-term lease of a 122,000-square foot state-of-the-art biomanufacturing facility in Smithfield, Rhode Island. The regenerative medicine company, which focuses on Advanced Wound Care and Surgical and Sports Medicine markets, will maintain its existing operations across multiple locations including Massachusetts, Alabama, California, Florida, and Switzerland. The Rhode Island expansion is subject to state and local tax incentives.
Organogenesis Holdings (Nasdaq: ORGO) welcomes the U.S. Centers for Medicare & Medicaid Services' decision on local coverage determination (LCD) for skin substitute grafts and cellular tissue-based products treating diabetic foot ulcers and venous leg ulcers. The LCD, effective February 12, 2025, is based on peer-reviewed clinical efficacy data. Organogenesis offers 4 products for diabetic foot ulcers, including NuShield, and 2 for venous leg ulcers. The company's NuShield product has been added to the list of covered products, marking a positive development for both the company and industry.
Organogenesis Holdings (NASDAQ: ORGO) reported Q3 2024 financial results with net revenue of $115.2 million, up 6% from Q3 2023. Advanced Wound Care revenue increased 7% to $108.0 million, while Surgical & Sports Medicine revenue grew 1% to $7.2 million. Net income reached $12.3 million ($0.09 per share), up from $3.2 million in Q3 2023. Adjusted EBITDA was $13.4 million, down from $16.0 million year-over-year. The company updated its FY2024 guidance, expecting net revenue between $455-480 million, representing 5-11% growth, with projected net loss between $12.3-0.6 million.
FAQ
What is the current stock price of Organogenesis Hldgs (ORGO)?
What is the market cap of Organogenesis Hldgs (ORGO)?
